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reviewer are systematic biases in industry-sponsored trials. These 
include misclassification of suicides, miscoding suicide attempts 
as emotional lability, and misreporting the true number of events 
[7, 8]. 
Healy and Whitaker [9] show that two suicides in the parox-
etine program that occurred during the lead-in phase were incor-
rectly recorded as placebo suicides. Sharma et al. [8] document that 
4 out of 16 deaths recorded in 70 antidepressant trials were misre-
ported by the drug manufacturer, in all cases favoring the active 
treatment. For example, a patient on venlafaxine who attempted 
suicide during the randomized treatment phase and who died 5 
days later in hospital was recorded as a post-study event because 
death occurred in the hospital when treatment was discontinued. 
These flaws in industry-sponsored antidepressant trials also ques-
tion the reliability of the highly cited FDA analysis, which was not 
based on the FDA’s own safety reviews but on the evaluations ob-
tained from the drug manufacturers [10].
To demonstrate that misreported suicides can substantially 
bias the results, we show in Table 1 that the suicide risk accord-
ing to a Bayesian random-effects meta-analysis (the method rec-
ommended by Ren et al. [6]) of the uncorrected data table was 
OR = 2.49, 0.82–45.32 (note the discrepancy to Hayes et al. [1]). 
With the two misclassified placebo suicides from the paroxetine 
program removed, the association was OR = 5.72, 1.36–427.45, 
and with data from the fluoxetine and bupropion programs in-
cluded (which increases power), it was OR = 6.34, 1.55–365.83. 
Finally, Hayes et al. [1] did not present meta-analytic results for 
suicide attempts, the single most important determinant of sui-
cide. Even when based on the uncorrected data table, our analy-
ses reveal a significantly increased risk of suicides and suicide 
attempts combined in antidepressant arms relative to placebo 
that was largely consistent across methods (e.g. Bayesian ran-
dom-effects meta-analysis: OR = 1.80, 1.19–3.33). The R-code is 
available online via https://osf.io/qzjva. These meta-analytic 
findings indicate that there is an increased suicide risk with an-
tidepressants.
We thank Hayes et al. [1] for their interest in our work and the 
opportunity to address important issues, which were not covered 
in our original paper [2]. We decided to replicate the findings from 
Khan et al. [3] without a meta-analytic method because, first, the 
statistical model should be comparable to the one Khan et al. used 
for this particular data table [3], and second, it should also closely 
resemble the model Khan et al. used in their previous analysis of 
the FDA database [4]. 
Hayes et al. [1] demonstrate that different meta-analytic 
methods produce varying results when events are very rare. How-
ever, some of their models (e.g., inverse-variance and DerSimo-
nian-Laird) are inappropriate for data with rare events and many 
zero-events in both arms [5, 6]. We further acknowledge that an 
ideal meta-analytic method would not only account for differ-
ences between new drug application programs, but also for dif-
ferences within programs, as every program consists of varying 
numbers of different trials, including placebo-controlled, active-
controlled, and even few open-label (safety extension) trials. Per-
haps the most important issue we had not addressed in our orig-
inal letter due to space limitations and firm opposition from a 
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Table 1. Summary estimates for different meta-analytic methods
Suicides Suicides and suicide attempts
original correcteda correcteda plus 
fluoxetine and bu-
propion
original correcteda correcteda plus 
fluoxetine and 
bupropion
Petob 1.74 (0.78–3.90) 2.41 (1.06–5.48) 2.48 (1.13–5.44) 1.57 (1.15–2.16) 1.65 (1.20–2.27) 1.72 (1.26–2.34)
Mantel-Haenszelc 1.98 (0.71–5.50) 3.96 (0.97–16.20) 4.37 (1.07–17.82) 1.70 (1.17–2.49) 1.83 (1.24–2.70) 1.94 (1.32–2.87)
Arcsine (risk difference 
in %)d 0.05 (0.00–0.17) 0.09 (0.02–0.21) 0.09 (0.02–0.20)
Exacte 1.91 (0.62–14.96) 3.49 (0.77–768.57) 3.71 (0.81–1491.41) 1.70 (1.17–2.57) 1.81 (1.23–2.78) 1.93 (1.31–2.97)
Bayesian random-effectsf 2.49 (0.82–45.32) 5.72 (1.36–427.45) 6.34 (1.55–365.83) 1.80 (1.19–3.33) 1.92 (1.27–3.36) 2.07 (1.36–4.06)
Original analysis 2.83 (1.13–9.67) 2.49 (1.74–3.70)
Figures are OR with 95% CI in parentheses. Our results for the Peto method are identical to those reported by Hayes et al. [1], but our results for both 
the Mantel-Haenszel and the Bayesian method differ due to different model specifications. OR, odds ratio; CI, confidence interval or credible interval 
(for the Bayesian meta-analysis). 
a Two suicides erroneously recorded in the placebo group from the paroxetine approval program removed. b With metafor package. c With metafor 
package. Contrary to the method applied by Hayes et al. [1], drug approval programs with zero events in both arms were included in the analysis and a 
continuity correction is thus not necessary with metafor. According to Bradburn et al. [5], common Mantel-Haenszel models with constant 0.5 continu-
ity correction introduce bias when events are rare. d With metafor package. The arcsine transformation has the advantage that no continuity correction 
is necessary. e With gmeta package. Using the approach suggested by Liu et al. [11]. f With JAGS program for R, using a model based on the parameters 
given by Hayes et al. [1]. The estimates are the medians of the posterior distribution. In our analysis, we used 8 chains, 1,000,000 burn-in samples, and 
5,000,000 resamples. All analyses were conducted with R, version 3.6.1 (R Core Team, 2019). See R-Code for details https://osf.io/qzjva.
